Why the study?
Does long-term warfarin therapy reduce plasma levels of prothrombin fragment 1 + 2 in patients with thrombotic disease compared to healthy subjects?
Does long-term warfarin therapy reduce plasma levels of prothrombin fragment 1 + 2 in patients with thrombotic disease compared to healthy subjects?
Answers are grounded in this paper and cite their sources.
Long-term oral anticoagulant therapy suppresses thrombin generation in parallel to the decrease in coagulation factors, as indicated by decreased F1 + 2 levels.
To assess the degree of haemostatic system activation, plasma levels of prothrombin fragment 1 + 2 (F1 + 2), a direct indicator for thrombin generation in vivo, were measured in 49 patients with thrombotic disease undergoing long-term warfarin therapy (Thrombotest values < or = 40%). In these patients, vitamin K dependent coagulation factors (factors II, VII, IX and X) were decreased together with the anticoagulant proteins C and S, but the mean plasma concentration of F1 + 2 was significantly decreased compared with 48 healthy subjects. In warfarin-treated patients, F1 + 2 was positively correlated with the Thrombotest value, factors II, VII, IX and X. When analysed according to the intensity of anticoagulation, patients with Thrombotest values less than 30% showed a significant decrease in F1 + 2, but the mean F1 + 2 level was normal in patients with Thrombotests higher than 30%. These findings indicate that long-term oral anticoagulant therapy suppresses thrombin generation approximately in parallel to the decrease in coagulation factors, and levels of F1 + 2 lower than healthy subjects are observed when Thrombotest values are less than 30%.
No takes yet. Share an insight, caveat, or question.
Takahashi et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: